Comparing the therapeutic effect of 1%Curcumin gel and placebo in the treatment of psoriasis skin disease

Comparing the therapeutic effect of 1%Curcumin topical gel and placebo in the treatment of mild to moderate psoriasis plaques

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017083136006N1

Enrollment

Registered

2017-09-19

Start date

2017-10-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque psoriasis (mild to moderate). Psoriasis vulgaris

Interventions

Intervention 1: In the intervention group

1%Curcumin gel will be used. patients will be asked to use the drug twice a day every 12 hours as a thin layer on the psoriasis plaques for two weeks. The questionnaires related to the quality of itch

Treatment - Drugs

In the intervention group

1%Curcumin gel will be used. patients will be asked to use the drug twice a day every 12 hours as a thin layer on the psoriasis plaques for two weeks. The questionnaires related to the quality of itc

In the control group? placebo will be used. patients will be asked to use the drug twice a day every 12 hours as a thin layer on the psoriasis plaques for two weeks. The questionnaires related to the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Mild to moderate psoriasis plaques (if the extent of body surface involved, is =5%); the absence of psoriatic arthritis; not using other medications for psoriasis in the recent month; patient consent to participate in the study; absence of any other disease requiring the use of systemic cytotoxic medications, immunosuppression, or taking psoriasis triggers medications; lack of lactation and pregnancy. Exclusion criteria: The presence of psoriasis in the face or genitalia; losing the patient for various reasons such as immigration or death; severe drug allergy to curcumin gel or placebo; dropped-out of the patient from the study; irregular use of medication.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mild to moderate plaque psoriasis. Timepoint: Before treatment, the second week of treatment, two weeks after the end of treatment. Method of measurement: Based on PASI-score.	—

Secondary

Measure	Time frame
Pruritus criterion before and at the end of treatment. Timepoint: Before treatment, the second week of treatment, two weeks after the end of treatment. Method of measurement: Based on itchy qol.;Quality of life before and at the end of treatment. Timepoint: Before treatment, the second week of treatment, two weeks after the end of treatment. Method of measurement: Based on dlqi.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPardis Vakili

Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran

vakilipardis@yahoo.com; vakili.p@ajums.ac.ir+98 61 3337 5717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026